市场调查报告书
商品编码
1608701
儿科临床试验市场:依阶段、依研究设计、依治疗领域、按地区Pediatric Clinical Trials Market, By Phase, By Study Design, By Therapeutic Area (Respiratory Diseases, Cardiovascular Diseases, and Neuropsychiatric Conditions, Oncology, Diabetes, and Others ), By Geography |
2024年儿科临床试验市场规模预计为175.4亿美元,预计2031年将达333.1亿美元,2024年至2031年复合年增长率为9.6%。
报告范围 | 报告详情 | ||
---|---|---|---|
基准年 | 2023年 | 市场规模(2024年) | 175.4亿美元 |
实际资料 | 2019-2023 | 预测期 | 2024-2031 |
预测期复合年增长率(2024-2031): | 9.60% | 预计金额(2031年) | 333.1亿美元 |
近年来儿科临床试验市场经历了显着成长。儿童慢性病盛行率的不断上升以及对新治疗方案的需求不断增长正在推动儿科临床试验产业的发展。此外,製药公司正在增加对儿童药物开发的投资。人们对罕见疾病的认识不断提高,加上监管机构要求对儿科药物进行临床评估的努力正在扩大市场机会。然而,由于伦理问题、特定年龄的药物代谢、招募困难以及对替代终点缺乏共识,进行儿科药物的临床试验比成人试验更加复杂和困难。然而,随着新治疗方法的出现以及公司不断努力开发儿童友善药物,儿科临床试验市场预计将在未来几年强劲成长。
全球儿科临床试验市场的成长是由儿童慢性病盛行率上升、对新治疗方法的需求不断增加以及旨在简化药物开发流程的监管努力所推动的。根据世界卫生组织估计,2021年全球将有超过2亿名儿童受到各种非传染性疾病的影响。鑑于大量未满足的需求,製药公司活性化投资于儿科特异性治疗方法的开发。美国食品药物管理局(FDA) 2012 年法案等有利法规要求对儿科药物进行上市前临床评估,扩大了市场机会。然而,儿科临床研究的复杂性和缺乏足够的替代终点继续对市场成长产生负面影响。与临床试验相关的高昂成本以及缺乏经验丰富的临床实验也阻碍了更广泛的市场采用。然而,产业相关人员和研究机构之间的持续合作,以新颖的方法解决问题,可能会支持未来的扩张。
本报告对全球儿科临床试验市场进行了详细分析,并列出了以2023年为基准年的预测期(2024-2031)的市场规模和复合年增长率。
它还揭示了各个细分市场的潜在商机,并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数,对全球儿科临床试验市场的主要企业进行概况分析。
主要公司包括 CSL Behring、赛诺菲、工业、Orchard Therapeutics plc.、Pharming Group NV、BioCryst Pharmaceuticals, Inc.、Ionis Pharmaceuticals, Inc.、Attune Pharmaceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnotical, Incceuticals、Arrowhead Pharmaceuticals, Inc.、Adverum Biotechnotical, Inc. 、CENTOGENE NV等
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
全球儿科临床试验市场报告针对该行业的各个相关人员,如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球儿科临床试验市场的各种策略矩阵,将有助于相关人员做出决策。
The pediatric clinical trials market is estimated to be valued at USD 17.54 Bn in 2024 and is expected to reach USD 33.31 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | 17.54 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 9.60% | 2031 Value Projection: | 33.31 Bn |
The pediatric clinical trials market is witnessing significant growth in recent times. Growing prevalence of chronic diseases among children and rising demand for new treatment options have boosted the pediatric clinical trials industry. Further, the market has witnessed rising investment from pharmaceutical companies for drug development targeting pediatric population. Growing awareness about rare diseases and various initiatives undertaken by regulatory bodies mandating clinical evaluation of drugs for pediatric use have augmented market opportunities. However, conducting clinical trials for pediatric drugs is more complex and challenging than adult trials due to ethical concerns, age specific drug metabolism, difficulty in recruitment, and lack of consensus over surrogate endpoints. Nevertheless, with emerging novel medical therapies and continuous efforts by players towards developing child-friendly drugs, the pediatric clinical trials market is poised to experience strong growth over the forthcoming years.
The global pediatric clinical trials market growth is driven by the rising incidence of chronic diseases among children, growing demand for new treatment modalities, and initiatives undertaken by regulatory bodies to streamline drug development process. In 2021, as per WHO estimates, over 200 million children suffer from various non-communicable illnesses worldwide. High unmet clinical needs have encouraged pharmaceutical companies to boost investments towards developing specialized treatments for pediatric population. Favorable regulations such as the U.S. Food and Drug Administration's amendments Act 2012 have mandated pre-marketing clinical evaluation of drugs for pediatric use, thereby augmenting market opportunities. However, complexities involved in pediatric clinical research and lack of sufficient surrogate endpoints continue to negatively impact market growth. High costs associated with trials and inadequate number of experienced clinical investigators also impede broader market adoption. Nevertheless, continual collaborations between industry players and research organizations to address issues through novel approaches will support future expansion.
This report provides in-depth analysis of the global pediatric clinical trials market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global pediatric clinical trials market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include CSL Behring, Sanofi, Takeda Pharmaceutical Company Limited, Orchard Therapeutics plc., Pharming Group N.V., BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Attune Pharmaceuticals, Arrowhead Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., KalVista Pharmaceuticals, and CENTOGENE N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global pediatric clinical trials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pediatric clinical trials market